Introduction Thymic stromal lymphopoietin (TSLP), an epithelial cytokine (alarmin), is a
central regulator of the immune response to inhaled environmental insults such as …

Monoclonal antibody therapies have significantly improved treatment outcomes for patients
with severe asthma; however, a significant disease burden remains. Available biologic …

Background Tezepelumab is a human monoclonal antibody that blocks thymic stromal
lymphopoietin, an epithelial-cell–derived cytokine implicated in the pathogenesis of asthma …

Background Tezepelumab is a human monoclonal antibody that blocks the activity of thymic
stromal lymphopoietin. SOURCE evaluated the oral corticosteroid-sparing effect of …

Asthma is a complex respiratory disease that varies in severity and response to treatment.
Several asthma phenotypes with unique clinical and inflammatory characteristics have been …

Interleukins (IL)-4 and-13 play a pivotal role in the pathobiology of type-2 asthma. Indeed, IL-
4 is crucially involved in Th2 cell differentiation, immunoglobulin (Ig) class switching and …

Group 2 innate lymphoid cells (ILC2s) are recently reported to play a more critical role in
allergic diseases. We previously identified that mesenchymal stromal cells (MSCs) elicited …

Background Phenotypic characteristics of patients with eosinophilic and noneosinophilic
asthma are not well characterized in global, real-life severe asthma cohorts. Research …

The heterogeneity of asthma makes it challenging to unravel the pathophysiologic
mechanisms of the disease. Despite the wealth of research identifying diverse phenotypes …

Asthma is a common disease affecting 350 million people worldwide, which is characterized
by airways inflammation and hyperreactivity. Historically diagnosis and treatment have been …